Kyverna Therapeutics, Inc. (KYTX) – What Are Analysts Saying About This Stock?

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been given an average rating of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $29.00.

Several equities research analysts recently commented on the stock. William Blair raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Needham & Company LLC set a $25.00 price objective on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, September 21st. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Finally, HC Wainwright reiterated a “buy” rating on shares of Kyverna Therapeutics in a research report on Thursday, October 22nd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KYTX. Legal & General Group Plc purchased a new stake in Kyverna Therapeutics during the 2nd quarter worth approximately $36,000. North Star Investment Management Corp. purchased a new position in shares of Kyverna Therapeutics in the third quarter valued at approximately $68,000. Oppenheimer & Co. Inc. purchased a new position in shares of Kyverna Therapeutics in the third quarter valued at approximately $78,000. Baldwin Wealth Partners LLC MA acquired a new stake in shares of Kyverna Therapeutics in the third quarter worth approximately $95,000. Finally, State of Wyoming acquired a new stake in shares of Kyverna Therapeutics in the second quarter worth approximately $97,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Stock Performance

Shares of KYTX stock opened at $5.16 on Wednesday. The company has a current ratio of 9.06, a quick ratio of 9.06 and a debt-to-equity ratio of 0.15. Kyverna Therapeutics has a 12-month low of $5.09 and a 12-month high of $13.67. The business’s 50 day moving average is $6.78 and its two-hundred day moving average is $8.05.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05. On average, equities analysts expect that Kyverna Therapeutics will post -2.70 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical-stage biotechnology company developing engineered T-cell therapies for patients with severe autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing B cells, which play a central role in many autoimmune disorders, with the goal of achieving deep and durable disease remission.

Kyverna’s lead investigational product, KYV-101, is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The treatment is being evaluated in clinical studies for conditions including lupus nephritis, systemic sclerosis, multiple sclerosis and other serious autoimmune diseases.